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Available online 19 January 2011Abstract Botulinum neurotoxins (BoNTs) inhibit cholinergic synaptic transmission by specifically cleaving proteins that are
crucial for neurotransmitter exocytosis. Due to the lethality of these toxins, there are elevated concerns regarding their possible
use as bioterrorism agents. Moreover, their widespread use for cosmetic purposes, and as medical treatments, has increased the
potential risk of accidental overdosing and environmental exposure. Hence, there is an urgent need to develop novel modalities
to counter BoNT intoxication. Mammalian motoneurons are the main target of BoNTs; however, due to the difficulty and poor
efficiency of the procedures required to isolate the cells, they are not suitable for high-throughput drug screening assays. Here,
we explored the suitability of embryonic stem (ES) cell-derived motoneurons as a renewable, reproducible, and physiologically
relevant system for BoNT studies. We found that the sensitivity of ES-derivedmotoneurons to BoNT/A intoxication is comparable
to that of primary mouse spinal motoneurons. Additionally, we demonstrated that several BoNT/A inhibitors protected SNAP-25,
the BoNT/A substrate, in the ES-derived motoneuron system. Furthermore, this system is compatible with immunofluorescence-Abbreviations: ES, embryonic stem; RA, retinoic acid; Shh, sonic hedgehog; EBs, embryoid bodies; WT, wild type; FACS, fluorescence-
activated cell sorter.
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196 E. Kiris et al.based high-throughput studies. These data suggest that ES-derived motoneurons provide a highly sensitive system that is
amenable to large-scale screenings to rapidly identify and evaluate the biological efficacies of novel therapeutics.
Published by Elsevier B.V.Introduction
Botulinum neurotoxins (BoNTs), composed of seven biochem-
ically distinct serotypes (BoNT/A–G) secreted by anaerobic
bacteria Clostridium botulinum, are extremely potent inhibi-
tors of neurotransmitter exocytosis at neuromuscular junc-
tions (Neale et al., 1999; Rossetto et al., 2006; Montecucco
and Molgo, 2005). Furthermore, BoNTs have been weaponized
(Arnon et al., 2001), and there is a significant concern that one
or more of these toxins could easily be used during an act of
bioterror (Wein and Liu, 2005). Indeed, BoNTs, as the most
poisonous of knownbacteria toxins (Lamanna, 1959), are listed
as category A bio-threat agents by the Centers for Disease
Control and Prevention (Centers for Disease Control and
Prevention, 2010).
On the other hand, and despite their unmatched
toxicities, pharmaceutical grade BoNT serotypes A and B
are widely used, in quantitatively minute, localized doses:
(i) to treat various movement and hyperactivity disorders
and (ii) cosmetically for wrinkle reduction (Jankovic, 2004;
Dolly et al., 2009; Brin, 2009). In fact, Botox (BoNT/A) treat-
ment is FDA approved and, according to statistics provided
by the American Society for Aesthetic Plastic Surgery
(American Society for Aesthetic Plastic Surgery, 2010), is
one of the top nonsurgical cosmetic procedures performed in
the United States. Furthermore, to extend BoNT potency for
clinical neurology applications, chimeric and modified BoNTs
have been generated using protein engineering methods to
expedite the toxin's cellular entry, increase its substrate
specificity, and extend its duration of activity in neuronal
and possibly nonneuronal cells (Dolly et al., 2009; Chen and
Barbieri, 2009; Wang et al., 2008; Foster et al., 2006).
However, as BoNTs are increasingly being used for
medical and cosmetic purposes, the possibility of accidental
overdosing in the clinic, in addition to unintentional
environmental exposure through contaminated food or
liquids, is also increasing. Moreover, as indicated above,
BoNTs represent a major concern with regard to counter-
bioterrorism efforts. Yet, there is still no effective thera-
peutic means for countering these toxins postneuronal
internalization (Montecucco and Molgo, 2005). To date,
there are only two FDA approved anti-BoNT antibodies:
babyBIG (human serum-derived anti-BoNT immunoglobulins)
and bivalent (BoNT A/B) equine toxin (Infant Botulism
Treatment and Prevention Program, 2010; Larsen, 2009).
However, the antibody treatments must be administered to
intoxicated individuals within a very narrow time frame to
prevent the progression of neuronal paralysis—since the
antibodies cannot inhibit the toxins postneuronal penetra-
tion. As a result, the antibodies are only marginally
beneficial for recovery, since patients still require respira-
tory aid for weeks. Hence, there is an urgent need to develop
novel and more effective medical treatments to limit/
counter BoNT intoxication (Burnett et al., 2005).
Mechanistically, BoNTs inhibit neurotransmitter exocytosis
by cleaving specific soluble N-ethylmaleimide-sensitive fusionprotein attachment (SNARE) proteins. The cleavage of SNARE
proteins results in impaired muscle function, respiratory
arrest, and, if mechanical respiration is not available, death
(Neale et al., 1999; BaldwinandBarbieri, 2009; Rossetto et al.,
1994). Structurally, BoNTs are composed of a heavy chain (HC)
(100 kDA), which is mainly responsible for neuronal internal-
ization, and a light chain (LC) metalloprotease (50 kDa)
(Grumelli et al., 2005; Simpson, 2004). The HC and the LC
are linked by a disulfide bridge (Montecucco and Molgo, 2005).
The C-terminal region of the BoNT HC interacts with SV2
(Synaptic Vesicle Protein 2) receptors, and mediates toxin
endocytosis (Dong et al., 2006; Mahrhold et al., 2006).
Following cellular entry, the LC dissociates from the HC and
cleaves SNAREproteins in the neuronal cytosol (Rossetto et al.,
2006). Importantly, it is the LC's proteolytic activity that is
responsible for the extreme potencies of these toxins; LC at
very low concentrations is sufficient to block the activity of a
motoneuron. For example, BoNT/A specifically removes 9
amino acids from the C-terminus of SNARE component
synaptosomal-associated protein of 25 kDA (SNAP-25), and
this simple cleavage is sufficient to inhibit neurotransmitter
release (Kalandakanond and Coffield, 2001; Apland et al.,
1999, 2003; Blasi et al., 1993; Bajohrs et al., 2004). Moreover,
while BoNT/A mainly targets motoneurons, it is stable in cells
for weeks (Adler et al., 2001; Keller et al., 1999; Fagan et al.,
2009), and its active form can travel in the nervous system and
reach distant synapses through retrograde transportation
(Caleo et al., 2009; Antonucci et al., 2008).
There is a significant need to develop novel therapeu-
tics to counter BoNT poisoning—especially postneuronal
internalization (Hakami et al., 2010). However, there are
currently no reliable, large-scale cell-based drug screening
assays to facilitate such research. This is mainly due to a
lack of relevant and well-characterized experimental
model systems. Specifically, while cell culture-based
assays employing mammalian neuroblastoma cells and
primary spinal cord cells from chickens or rodents have
been used previously to study the effects of small
molecules on BoNT intoxication (Hakami et al., 2010;
Sheridan et al., 2005; Coffield and Yan, 2009; Stahl et al.,
2007; Dong et al., 2004; Pellett et al., 2007), these
models possess limitations. For example, immortalized
cells can be produced in large quantities, but lack
sensitivity (Hakami et al., 2010). Moreover, such cell
lines carry tumorigenic properties, and therefore do not
mimic physiologically normal/relevant conditions. In con-
trast, primary embryonic spinal cord cells from rodents are
physiologically relevant and very sensitive to BoNT
intoxication (Keller et al., 2004); however, these cells
are very difficult to obtain in large quantities because
primary embryonic spinal motoneurons are postmitotic.
Moreover, spinal cord dissections are technically challeng-
ing and inconsistent, as they can yield different ratios of
motoneurons (versus other cells) from culture to culture.
Therefore, these strategies are not optimal for developing
high-throughput, neuron-based screening assays.
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be differentiated from embryonic stem (ES) cells (Miles et al.,
2004; Wichterle et al., 2002, 2009; Wichterle and Peljto,
2008). Therefore, we tested the hypothesis that ES-derived
motoneurons can be used as a renewable cellular source for
large-scale drug screening assays to identify BoNT therapeu-
tics, as well as to examine the general biological effects of
intoxication on the host's cellular pathways. The results
presented herein demonstrate that ES-derived motoneurons
do provide a highly sensitive, easily accessible, and renewable
cell model system that is compatible with high-throughput
screening and experimentation. Furthermore, the presented
cellularmodel is also a unique tool for investigating host-based
genes and proteins that are responsive to BoNT intoxication.Significantly, while this study focused on BoNT/A intoxication,
the established model is also applicable for studying all other
BoNT serotypes.
Results
Differentiation and characterization of mouse
ES-derived motoneurons
It is established the mouse ES cells can be differentiated into
functional motoneurons via the application of retinoic acid
(RA) and Sonic Hedgehog (Shh) protein (Wichterle et al.,
2002, 2009; Wichterle and Peljto, 2008). For these experi-
ments, we employed an HBG3 ES cell line carrying the
motoneuron-specific transcription factor Hb9 promotor,
which drives the expression of the enhanced green fluores-
cence gene (eGFP). This allows for the identification of
differentiated motoneurons based on eGFP expression
(Wichterle et al., 2002). In addition, such specific eGFP
expression permits motoneuron isolation and/or enrichment
using a fluorescence-activated cell sorter (FACS).
Pluripotent ES cells were cocultured with primary mouse
embryonic fibroblasts, and at 70–80% confluency, the ES
cells were separated from the fibroblasts (see Materials and
methods), aggregated as embryoid bodies (EBs), and induced
in suspension culture with RA, Shh, and Purmorphamine.
After 7 days in suspension, the EBs were dissociated gently
and plated onto Matrigel-coated cell culture dishes/slides for
an additional 3 days prior to characterization.
Western blot analyses of differentiated ES cell lysates were
performed at various time points to demonstrate changes in
the protein expression profile of markers that are character-
istic of stem cells, neuronal cells, and motoneurons. First, we
found that eGFP expression increased in response to moto-
neuron-inducing factors, suggesting activation of the moto-
neuron-specific HB9 promotor (Fig. 1A). Furthermore,
expressions of the neural markers Tau (Tau5) and β-III
tubulin-specific Tuj1 were transiently up-regulated. Similarly,
after Day 5, choline acetyltransferase (ChAT), an enzyme that
is required for the synthesis of the neurotransmitter acet-
hylcholine, was also up-regulated (Fig. 1A). By contrast,
pluripotency markers Oct4 and Sox2 that are expressed in ES
cells were down-regulated during differentiation. TakenFigure 1 Characterization of ES-derived motoneurons.
(A) Western blot analyses of cellular markers expressed at
different stages of the differentiation process. Markers included
eGFP driven by Hb9 motoneuron promotor (Hb9-eGFP) genes
expressed by pluripotent ES cells, Oct4 and Sox2; neuronal cells,
Tuj1 and Tau; and postmitotic motoneurons, ChAT protein.
Similarly, SNAP-25 protein expression, the only-known intracel-
lular target of BoNT/A, was also evaluated. Total protein loaded
per lane was 10–15 μg and GAPDH was used as loading control.
(B) Immunostaining for neural markers in the differentiated
cultures. Cells from embryoid bodies dissociated at Day 7 and
cultured on Matrigel-coated culture slides for an additional
3 days were immunostained with antibodies against neuronal
marker, NeUN; postmitotic motoneuron markers Hb9, and Isl1;
SNARE protein, SNAP-25, and SV2A, the receptor required for
BoNT/A entry into neurons. Shown are also the Hb9-eGFP and
DAPI nuclear staining. The scale bar is 50 μm.
198 E. Kiris et al.together, these data suggest that the protocol used is very
effective for differentiating ES cells into the neuronal lineage.
To further characterize (at the cellular level) the identity
of the differentiated cells, immunocytochemistry was used
to investigate the expression profiles of specific motoneuron
markers (Fig. 1B and Supplementary Fig. 1). Importantly, we
confirmed that the Hb9::GFP expression overlaps accurately
with the endogenous Hb9 protein. The specificity of the
differentiation procedure was further demonstrated by the
expression of motoneuron markers Isl1 (Fig. 1B) and LIM3
(Supplementary Fig. 1). Moreover, confocal analyses indi-
cated that ChAT was expressed by all GFP+cells, thereby
indicating the mature phenotype of the motoneurons.
Occasionally, some GFP-negative cells also expressed ChAT
with other neuronal markers (such as NeUN (Fig. 1B), Tau,
and Tuj1 (Supplementary Fig. 1)). These data suggested that
the majority of the differentiated cells at Day 10 were
motoneurons, but that other neural cells could also form.
FACS analysis quantification of GFP+cells at Day 7
indicated a motoneuron differentiation rate of 30–40%,
which is consistent with the efficiency observed in previous
studies employing similar protocols (data not shown)
(Wichterle and Peljto, 2008).
SNAP-25 protein and the SV2A receptor are present
in ES-derived motoneurons
SNAP-25, the intracellular target of the BoNT/A LC, is required
for acetylcholine exocytosis and is abundantly expressed inFigure 2 Concentration-dependent effects of BoNT/A on SNAP-2
mouse spinal neurons, and DRG neurons, and the motoneuron-like NS
uncleaved SNAP-25 protein following cell treatment with various co
quantification of each blot shown at the bottom of the x axis. The t
mediated cleavage fragment. Inset in each panel is representative
neuronal marker NeUN (red), Hb9-eGFP (green), and DAPI (blue); (B)
cytoplasmic neuronal markers Tuj1 (red) and DAPI (blue); (D) immor
total Tau protein and DAPI imaging. The scale bar is 50 μm.primary spinal motoneurons (Montecucco and Molgo, 2005;
Keller and Neale, 2001). Therefore, we investigated its
expression in ES-derived motoneurons to establish the
relevance of these cells with respect to BoNT/A intoxication
experiments. Western blot analyses revealed increased SNAP-
25 protein expression during differentiation up to Day 10
(Fig. 1A). Immunocytochemical analyses further confirmed the
presence of SNAP-25 in the ES-derivedmotoneurons. Similarly,
the SV2A receptor, which is crucial for BoNT/A entry into the
neuron cytosol, was also expressed by GFP+motoneurons
(Fig. 1B). Thus, the presence of BoNT/A receptor SV2A and the
toxin's intracellular target (i.e., SNAP-25) in the differentiated
motoneurons strongly suggested that this system should be
sensitive to BoNT/A intoxication.
ES-derived motoneurons are acutely sensitive to
BoNT/A intoxication in a dose-dependent manner
Since ES-derivedmotoneurons express both SV2A and SNAP-25,
we evaluated their sensitivity to various concentrations of
BoNT/A (0–1000 pM) after 3 h (Fig. 2A). Via Western blot
analysis, we visualized the BoNT/A-mediated cleavage of
SNAP-25 by examining its shift inmolecular weight from ~25 to
~24 kDa. As shown in Fig. 2A, we observed a direct, dose-
dependent correlation between cleaved SNAP-25 and BoNT/A
concentration. ES-derivedmotoneurons were very sensitive to
BoNT/A, since concentrations as low as 10 pM caused SNAP-25
cleavage (Fig. 2A). Next, we compared the BoNT/A intoxica-
tion sensitivity of ES motoneurons with the BoNT/A5 protein cleavage in mouse ES-derived motoneurons, primary
C-34 cell line. (A–D) Graphic representation of the percentage of
ncentrations of BoNT/A (0–1000 pM). The graphs represent the
op band is uncleaved SNAP-25; the bottom band is the BoNT/A-
image of: (A) ES-derived motoneuron cultures stained with the
primary mouse spinal cord cells and (C) DRG neurons stained with
talized NSC-34 cells stained with neuronal marker Tau5 (red) for
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DRG neurons (Fig. 2B). As previously reported, primary spinal
cord cells exhibit BoNT/A sensitivity at concentrations that are
comparable to ES motoneurons (although starting at 25 pM
(Keller et al., 2004); Fig. 2B). DRG neurons were found to be
less sensitive to BoNT/A intoxication than either ES-derived
motoneurons or primary spinal cord cells, since the BoNT/A
effect became apparent at 100 pM (Fig. 2C). Additionally,
immortalized mouse spinal cord cells derived from the NSC-34
cell linedemonstrated a complete lack of sensitivity to BoNT/A
within the toxin concentration range that was examined in this
study (Fig. 2D). However, this result was not surprising, as
immortal neural cell lines have been shown to usually require
either higher BoNT concentrations or longer exposure times
(up to 48 h) to display SNAP-25 cleavage (Hakami et al.,
2010; Stahl et al., 2007). Taken together, these data suggest
that ES-derived motoneurons are at least as sensitive to
BoNT/A intoxication as primary spinal cord neurons (as
revealed by the SNAP-25 cleavage profiles shown in Fig. 2).
Moreover, these experiments also indicated that, although
other cells can arise during the ES motoneuron differentia-
tion protocol, no further purification or enrichment of the
ES-derived motoneurons is required to obtain a BoNT/A-
mediated SNAP-25 proteolysis level comparable to that
observed for primary cells.
Evaluation of the time dependency of BoNT/A action
on SNAP-25 proteolysis
To further evaluate the effect of internalized BoNT/A over
time, ES-derivedmotoneurons were treatedwith 1 nM BoNT/A
for 1 h, washed with media to remove extracellular toxin, and
lysed at different time points (Fig. 3).Western blot analyses of
the cell lysates indicated that after only 1 h exposure, 1 nM
BoNT/A cleaved 41% of the SNAP-25 in our ES motoneurons
(Fig. 3). After 1.5 h, 70% of the SNAP-25 was cleaved (Fig. 3).
These data suggest that the BoNT/A-mediated cleavage of
SNAP-25 is rapid and effective, as observed by the fact that
cleavage of this protein was very close to a plateau point afterFigure 3 Time-dependent effects of BoNT/A on SNAP-25
cleavage. Western blot analysis and graphical representation
of BoNT/A-mediated cleavage of SNAP-25 over time. Cultures
were exposed to 1 nM BoNT/A for 1 h, after which time the toxin
was removed and cells were lysed at the indicated time points.
The top band in the Western blot is the uncleaved SNAP-25; the
bottom band is the BoNT/A-mediated cleavage fragment.only 1.5 h postintoxication. Therefore, a 1.5- to 3-h incubation
time frame is reasonable for assays to screen inhibitors to
counter BoNT/A poisoning in already intoxicated cells.BoNT/A inhibitors impede SNAP-25 proteolysis in ES
cell-derived motoneurons
To examine if the observed SNAP-25 cleavage in ES-derived
motoneurons was BoNT/A specific, we examined the effects
of three known inhibitors on the toxin's efficacy. We first
used the plant protein TVL, an extracellular BoNT antagonist
that binds to cell surfaces and interferes with BoNT/A entry
into neurons (Coffield and Yan, 2009; Bakry et al., 1991).
Following differentiation, motoneurons were treated with
TVL for 1 h and incubated with BoNT/A for 3 h. The media
were then removed, and the cells were rinsed with fresh
media three times (to remove any extracellular toxin). As
shown in Fig. 4, TVL pretreatment blocked BoNT/A-mediated
SNAP-25 proteolysis, providing an effect similar to that
observed in primary isolated motoneurons.
Similar SNAP-25 protection was also obtained employing
the neutralizing antibody 4A2–4, which inhibited BoNT/A-
mediated SNAP-25 cleavage in a dose-dependent manner.
The same level of protection has also been observed using a
chick primary motoneuron assay (Fig. 4) (Stahl et al., 2007;
Nuss et al., 2010). Finally, we examined the effect of
bafilomycin A1, an ATPase inhibitor that blocks endosome
acidification, which is a process required for receptor-
mediated BoNT entry into the neuronal cytoplasm (for all
BoNT serotypes) (Keller et al., 2004; Simpson et al., 1994;
Savino and Maus, 1991). ES-derived motoneurons were
incubated with BoNT/A and various concentrations of
bafilomycin A1 for 3 h, and then washed 3 times with fresh
media to remove extracellular toxin. As shown in Fig. 4,Figure 4 Inhibition of BoNT/A-mediated SNAP-25 cleavage
with BoNT/A neutralizing antibodies, Triticum Vulgaris Lectin
(TVL) and bafilomycin A1. Western blot analysis and graphical
representation of BoNT/A-mediated cleavage of SNAP-25 in ES
cell-derived motoneurons incubated with 1 nM BoNT/A in the
presence of the indicated inhibitors for 3 h. Note that while 1 μM
TVL only partially blocked SNAP-25 cleavage, bafilomycin A1
completely inhibited BoNT/A-mediated SNAP-25 cleavage at any
concentration, and the efficacy of the 4A2–4 antibody tightly
correlates with the antibody to toxin ratio.
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all concentrations. Overall, these data strongly suggest that
the ES-derived motoneuron cell system can be used to
effectively evaluate inhibitor-mediated SNAP-25 protection
in the presence of intracellular BoNT/A.ES-derived motoneurons are applicable for
high-throughput assays measuring BoNT/A activity
Immunofluorescence-based high-throughput studies to screen
compounds at high speed (to measure their abilities to inhibit
BoNT/A-mediated proteolysis) would require (i) specific
antibodies to quantify protein cleavage, and (ii) sensitive
cell culture systems that are amenable to large-scale studies.
We previously developed BoNT/A cleavage-sensitive (BACS)
antibodies, which are highly specific to full-length SNAP-25,
but not to truncated fragments resulting from BoNT/A
cleavage (Nuss et al., 2010). These antibodies, when used
in conjunction with commercially available noncleavage-
sensitive SNAP-25 antibodies, are unique biological tools to
quantify SNAP-25 cleavage in high-throughput studies. Herein,
with the knowledge that ES-derived motoneurons are highly
sensitive to BoNT/A, we sought to determine whether this
system is compatible with immunofluorescence-based high-
throughput studies, i.e., high content imaging (Panchal et al.,
2010) and Li-Cor imaging assays (Nuss et al., 2010).Figure 5 Measuring BoNT/A activity in cell-based assays using Bo
motoneurons were fixed and immunolabeled with antibodies to dete
and full-length SNAP-25 (BACS antibody labeling) (red). The nuclei
BoNT/A intoxication, truncated SNAP-25 was recognized by total SNA
reduction in red fluorescence. (B) High content imaging assay for
treated with a range of BoNT/A concentrations (0–1000 pM) and follo
and BACS antibodies as described in part A. (C) Licor imaging assay for
BoNT/A (0–1000 pM), incubated for 3 h, and fixed and stained with
response in both the high content imaging and the Li-Cor imaging
condition, images from 6 fields/well were acquired with the script
regions. Error bars represent standard errors of the averages.As a prelude, we first verified the efficacy of BACS
antibodies in this system using high content imaging. Mouse
ES cell-derived motoneurons were cultured in 96-well
plates and immunolabeled with total SNAP-25 (N-terminal-
specific antibody staining) (green) and full-length SNAP-25
antibodies (BACS antibody staining) (red) in the control and
BoNT/A intoxicated samples. As shown in Fig. 5A, a 3 h
BoNT/A (1 nM) treatment diminished immunostaining
resulting from the BACS antibodies (red), whereas immu-
nostaining with the N-terminal-specific antibody was not
affected by BoNT/A exposure (lower panels). Using a high
content imaging assay, we next measured the effects of
BoNT/A at varying concentrations (0–1000 pM) on SNAP-25
cleavage with BACS antibodies (following 3 h intoxication)
(Fig. 5B). The ratio of the integrated fluorescence in-
tensities in both channels was used to measure the change
in SNAP-25 cleavage as a function of BoNT/A concentration
(Fig. 5B). We further tested the utility of a simple scanning
fluorescence assay, Li-Cor imaging, for measuring intracel-
lular BoNT/A activity under similar conditions in 96-well
plates (Fig. 5C). Cells were treated with increasing doses of
BoNT/A (0–1000 pM), incubated for 3 h, and fixed and
stained with the antibody combinations described above.
Plates were then imaged and analyzed using a Li-Cor
Odyssey infrared imaging system (Nuss et al., 2010). The
measured dose response in both high content imaging and
Li-Cor imaging assays showed a BoNT/A concentration-NT/A cleavage-sensitive (BACS) antibodies. (A) ES cell-derived
ct total SNAP-25 (N-terminal-specific antibody labeling) (green)
in all images were labeled with Hoechst dye (blue). After a 3 h
P-25 antibodies, but not by BACS antibodies, which resulted in a
measuring BoNT/A activity. ES cell-derived motoneurons were
wing a 3-h incubation were fixed and stained with total SNAP-25
measuring intracellular BoNT/A activity. Cells were treated with
the antibody combinations described above. The measured dose
assays correlated well with BoNT/A concentrations. For each
calculating the integrated fluorescence intensities in whole cell
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experiments utilizing N-terminal-specific SNAP-25 antibo-
dies (Fig. 2) exhibited a similar dose-dependent change in
SNAP-25 (Figs. 5B and C). Taken together, these data
suggest that ES-derived motoneurons can serve as a
renewable cell source for immunofluorescence-based high-
throughput assays to measure BoNT/A activity by detecting
SNAP-25 proteolysis with BACS antibodies.Discussion
Efficient cell-based, high-throughput assays should employ
cell culture systems that are: (i) physiologically relevant,
(ii) sensitive, (iii) consistent, (iv) well-characterized, and
(v) renewable. The primary goal of this study was to establish
a physiologically relevant motoneuron cell culture model
suitable for the identification of BoNT inhibitors using a high-
throughput approach. Based on our results, we have
demonstrated that ES-cell derived primary neurons can
provide such a system, as they can be produced in relatively
large quantities, are very sensitive to BoNT intoxication, and
are suitable for the biochemical analyses of cellular path-
ways that are affected during BoNT intoxication.
Although primary mouse embryonic spinal motoneurons
are ideal for BoNT studies, the difficulty in obtaining and
culturing these cells makes them unattractive for high-
throughput screening purposes. Specifically, these cells are
difficult to obtain in large quantities, as only 5000–15,000
cells per embryo can be obtained (Wiese et al., 2009).
Moreover, it is difficult to obtain “pure” motoneurons
because other cells are present in the dissected spinal
cord. Consequently, to attempt to address these issues,
several methods have been established to isolate or enrich
primary motoneurons from dissected spinal cords. These
include either simple density-based techniques, or more
advanced antibody-based isolations (Wiese et al., 2009;
Camu and Henderson, 1992). However, these methods have
provided only varying degrees of success, require expensive
reagents, are time consuming, and yield limited quantities of
motoneurons. Therefore, we tested a previously established
ES cell-to-motoneuron differentiation methodology to obtain
large quantities of mammalian motoneurons.
As for the characterization of this system, our results are in
line with other studies utilizing the HBG3 cell line, thus
indicating that differentiated motoneurons exhibit the mor-
phological and physiological properties of their in vivo
counterparts, including the formation of cell processes and
the expression of motoneuron-specific markers (Miles et al.,
2004; Wichterle et al., 2002; Soundararajan et al., 2006)
(Figs. 1 and 2, and Supplementary Fig. 1). It is also noteworthy
to report the observation that, on transplantation, these
motoneurons successfully integrate into the chick spinal cord
(Wichterle et al., 2002). Furthermore, in line with the
literature (Miles et al., 2004; Harper et al., 2004), we have
found that differentiatedmotoneurons can innervate and lead
to postsynaptic acetylcholine receptor clustering, which is
detectable by alpha-bungarotoxin labeling when cocultured
with C2C12 skeletal muscle cells, thereby suggesting neuro-
muscular junction formation (Supplementary Fig. 2). Addi-
tionally, we have also found that ES-derived motoneurons
exhibit the same neurotrophin receptor expression profilingthat is observed for embryonic spinal motoneurons (data not
shown) (Moscatelli et al., 2009; Domeniconi et al., 2007; Pitts
et al., 2006).
Previous research employing mammalian and chick pri-
mary cells has demonstrated that spinal motoneurons are
extremely sensitive to BoNT/A when compared to poorly
sensitive DRGs. Our analysis is consistent with those findings,
indicating that ES cell-derived motoneurons, which are
equivalent to primary spinal motoneurons, are more sensitive
to BoNT/A than DRG neurons (Fig. 2). Moreover, we confirmed
that the NSC-34 cell line also fails to respond effectively to
BoNT intoxication under the conditions that we employed
(Fig. 2), further suggesting that, contrary to our system, these
cells are not adequate for BoNT toxicity studies.
Although the described ES-derived motoneuron model
leads to the generation of fully functional motoneurons,
other cells also arise when applying the differentiation
protocol. However, it should be noted that primary
motoneurons suffer from a similar limitation, with other
cells also being isolated during the plating of the dissected
spinal cords. Irrespective, ES-derived motoneurons, without
further isolation or enrichment, are very sensitive to BoNT/A,
thereby providing a robust readout of its toxicity (Fig. 2).
Moreover, since immunofluorescence analysis (Fig. 1) showed
that nonneuronal cells express relatively low levels of SNAP-25
compared to GFP+motoneurons, and the receptor required
for BoNT entry into the cells, SV2A, is mainly expressed in
GFP+cells, it is unlikely that nonneuronal cells present in our
cultures significantly contributed to the pool of truncated
SNAP-25 after 3 h of BoNT/A intoxication. If needed, eGFP
expression, which is under the control of the motoneuron-
specific Hb9 promotor, would allow for the isolation of pure
or enriched motoneuron populations by FACS. Indeed, we
have performed such experiment and found that FACS-sorted
motoneurons exhibit elevated sensitivity to BoNT/A intoxi-
cation (data not shown). However, sorted cells do not survive
well unless they are cultured on skeletal muscle cells, which
are believed to secrete neurotrophic factors required to
regulate the growth and maturation of motoneurons.
Regardless, although other cells also arise during directed
motoneuron differentiation, the non-FACS-sorted motoneur-
ons provide a robust and sensitive system in which BoNT/A-
mediated SNAP-25 proteolysis can be quantified (Fig. 2).
A large body of biochemical and cellular biology data
support the conclusion that BoNT-mediated SNAP-25 cleavage
inhibits cholinergic exocytosis, leading to the paralysis
associated with the disease state botulism (Kalandakanond
and Coffield, 2001; Apland et al., 1999, 2003; Blasi et al.,
1993; Bajohrs et al., 2004). This is a strong indicator that
SNAP-25 cleavage is a critical readout to assess the effects of
potential BoNT inhibitors. Although functional assays such as
neurotransmitter release assay could be also utilized, the
SNAP-25 cleavage assay allows us to directly monitor BoNT/A
activity by detecting cleavage of its endogenous substrate and
serves as the most time-efficient and sensitive assay for large-
scale BoNT/A inhibitor screenings. Herein, we demonstrated
that: (i) ES-derivedmotoneurons are very sensitive to BoNT/A-
mediated SNAP-25 cleavage (Figs. 2 and 3), (ii) the efficacies
of BoNT/A inhibitors can be determined in these motoneurons
by quantifying SNAP-25 protection during intoxication (Fig. 4),
and (iii) immunofluorescence-based high-throughput studies,
taking advantage of both renewable motoneurons and BACS
202 E. Kiris et al.antibodies, can be successfully utilized to screen BoNT
inhibitors at high speed (Fig. 5) (Nuss et al., 2010).Conclusions
Directed differentiation of ES-cell motoneurons, without the
need for further purification or enrichment, can provide a
very efficient, sensitive, and reliable cell system that may be
used to facilitate both basic research, geared toward
understanding the biological effects of BoNTs on motoneur-
ons, and high-throughput drug discovery efforts to identify
novel inhibitors/antagonists of BoNTs.Materials and methods
Directed differentiation of mouse ES cells into
motoneurons
Mouse ES cells (HBG3 cell line), in which GFP expression is
driven by mouse motoneuron-specific Hb9 promotor, were a
kind gift from Dr. Thomas M. Jessell and Dr. Hynek Wichterle
(Columbia University, New York, NY). The directed differen-
tiation of HBG3 cells into spinal motoneurons was achieved by
retinoic acid/Sonic Hedgehog/Purmorphamine based-induc-
tion methods, as described previously (Miles et al., 2004;
Wichterle et al., 2002, 2009; Wichterle and Peljto, 2008; Li
et al., 2008), butwith slightmodifications. Briefly, pluripotent
ES cells were maintained on mitomycin-inactivated primary
mouse embryonic fibroblast (MEF) cells in HBG3 medium. The
medium consisted of DMEM for ES cells (Chemicon, Billerica,
MA) supplemented with 15% ES-cell tested fetal bovine serum
(Hyclone, Waltham, MA), 1% Nucleosides (Chemicon), 1000
Unit/ml Leukemia Inhibitory Factor (LIF) (Millipore, Billerica,
MA), β-mercaptoethanol (final 0.1 mM), 1% penicilin/strepto-
mycin, 1% Glutamax, and 1% nonessential amino acids. Unless
otherwise stated, all reagents were obtained from Invitrogen
(Carlsbad, CA). For motoneuron induction, the ES cells were
trypsinized and resuspended in differentiation medium
including 1:1 Advanced DMEM/F12 plus Neurobasal medium
supplemented with 1% penicilin/streptomycin, 1% Glutamax,
β-mercaptoethanol (final 0.1 mM), and 15% Knockout serum
replacer. To remove MEFs by selective adherence, the single
cell mixtures were then plated onto tissue culture-treated
plates for 30 min. MEFs adhered to the plates more tightly
than ES cells. ES cells in the supernatant were collected,
counted using a Cellometer AutoT4 (Nexcelom Biosciences,
Lawrence, MA), and seeded onto AggreWell 400 (Stem Cell
Technologies, Vancouver, Canada) plates, at a density of 500
cells per microwell, to form embryoid bodies. EBs were
harvested the next day (Day 1), and maintained in suspension
culture (in fresh differentiation medium) for an additional
24 h. Following 2 days of differentiation, EBswere treatedwith
retinoic acid (1 μM, Sigma, St. Louis, MO) for 24 h to induce
neuralization and caudalization, and then Sonic Hedgehog
(100 ng/ml, R&D Systems, Minneapolis, MN) protein was added
to the same medium on Day 3 to induce motoneuron
specification. Purmorphamine (Calbiochem, Gibbstown, NJ)
was added to the cultures at a concentration of 1 μM (24 h after
Shh was added (Day 4)). On Day 5, EBs were transferred to
dishes including fresh motoneuron medium consisting of 1:1Advanced DMEM/F12 plus Neurobasal medium, which was
supplemented with 1% penicilin/streptomycin, 1% Glutamax,
and 2% B27 serum-free supplement (Invitrogen), brain-derived
neurotrophic factor (10 ng/ml, Chemicon), Glial cell-derived
neurotrophic factor (100 ng/ml, R&D Systems), Cliary-derived
neurotrophic facors (10 ng/ml, Chemicon), andNeurotrophin 3
(10 ng/ml, Chemicon). Finally, on Day 7, EBs were dissociated
using a papain dissociation system (Worthington, Lakewood,
NJ), and plated onto Matrigel (BD Biosciences, San Jose, CA)-
coated dishes for an additional 3 days to allow for the degree of
neurite elongation required for experimental purposes. The
efficiency of motoneuron differentiation indicated by GFP
expression was quantified using a fluorescence-activated cell
sorter (FACSCalibur Instrument, BD Biosciences).
Isolation and culture of primary mouse spinal cord
cells and dorsal root ganglion (DRG) neurons
Embryonic spinal motoneurons and DRG cells were dissected
and cultured from wild-type E13.5-old mouse (C57BL/6)
embryos as described previously (Wiese et al., 2009), but
with modifications. Briefly, dissected embryonic spinal cord
and DRG cells were dissociated using a papain dissociation
system for 30 min at 37 °C, according to the manufacturer's
protocol. Dissociated cells were then pelleted and triturated
until evenly suspended in medium containing papain inhib-
itor. Following, intact cells were separated from tissue
fragments with a discontinuous density gradient provided in
the papain dissociation kit. The cell population was enriched
with motoneurons by selective adherence. The single cell
mixtures were plated onto tissue culture-treated dishes for
30 min. Nonneuronal cells adhered to the dishes more tightly
than neuronal cells. The neuronal cells that remained in the
supernatant were collected, counted, and plated onto
Matrigel-coated 6-well culture plates in motoneuron media
including neurotrophic factors (as described above) for
5 days prior to the addition of toxin.
Culture and differentiation of NSC-34 cells
NSC-34 cells were purchased from CELLutions Biosystems Inc.
(Ontario, Canada), and cultured and differentiated as
described previously (Cashman et al., 1992). Briefly,
undifferentiated cells were maintained in media consisting
of high-glucose DMEM supplemented with 10% fetal bovine
serum (Hyclone), 1% penicillin/streptomycin, and 1% Gluta-
max. For the experiments, cells were differentiated in
medium containing 1:1 DMEM/Ham's F12 supplemented with
1% fetal bovine serum, 1% penicillin/streptomycin, and 1%
nonessential amino acids for 7 days.
Western blot analysis for the characterization of
ES-derived motoneurons
The ES cells and differentiated cells were harvested at
different stages, washed with PBS, and lysed in NP-40 cell
lysis buffer. The lysates were then centrifuged at 10,000 rpm
for 10 min at 4 °C. The total protein concentration of the
supernatant was determined using a BCA protein assay kit
(Thermo Scientific). Equal amounts of total protein were run
on 4–12 or 14% polyacrylamide gels (Invitrogen), transferred
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1 h, and incubated with primary antibodies against eGFP
(Invitrogen), GAPDH (Millipore), Tuj1 (R&D Systems), Tau5
(Thermo Scientific), Sox2 (Millipore), Oct4 (Sigma), choline
acethyltransferase (Millipore), and SNAP-25 (BD Bios-
ciences), in TBST buffer containing 5% milk overnight at
4 °C. Horseradish peroxidase-conjugated secondary antibo-
dies used in these experiments were obtained from Millipore.
The membrane was visualized using a Pierce ECL Western
detection kit (Thermo Scientific). The immunoblotting
results were scanned with a Syngene (Frederick, MD) gel
documentation and analysis system.
Immunocytochemistry
Day 7 differentiated embryoid bodies were dissociated with
papain and plated onto Matrigel (BD Biosciences)-coated 4-
or 8-well BD BioCoat culture slides for 3 days. Following, cells
were fixed in 4% paraformaldehyde for 10 min and permeabi-
lized with 0.1% Triton X-100. After being blocked with 1%
appropriate serum, the cells were stained with antibodies
against NeUN (Millipore), Hb9 (Developmental Studies Hybrid-
oma Bank (DSHB, Iowa City, IA)), Isl1 (DSHB), SV2A (Millipore),
and SNAP-25 (BD Biosciences) (as shown in Fig. 1B) as well as
for Tau5 (Thermo Scientific), Tuj1 (R&D Systems), ChAT
(Millipore), and LIM3 (Millipore) (as shown in Supplementary
Fig. 1). Primary antibodies were incubated overnight in PBS
with 10% serum (or 1% BSA). Appropriate secondary antibodies,
conjugated with Alexa488 and Alexa 594, were incubated the
following day for 2 h at room temperature. Cells were washed
in PBS and mounted in ProLong Gold antifade reagent with
DAPI (Invitrogen) for nuclear staining. Images were collected
employing Zeiss ApoTome (ImagerZ1) and Zeiss confocal
microscopes (Zeiss, Thornwood, NY).
BoNT intoxication and immunoblotting analyses to
quantify SNAP-25 cleavage
Neuron cultures (Day 10) were intoxicated with various
concentrations of BoNT/A (MetaBiologics, Madison, WI) and
incubated at 37 °C for 3 h. Following intoxication, toxin-
containing media were removed and cells were rinsed with
fresh motoneuron media three times. SNAP-25 protein
cleavage was quantified using standard immunoblotting
procedures employing SNAP-25 antibodies as described
previously (Nuss et al., 2010). For the Western blot analysis
shown in Fig. 3, ES-derived motoneurons (Day10) were
intoxicated for 1 h, and then toxin remaining in the medium
was cleared with washing. Following, cells were incubated at
37 °C for additional time frames, as indicated in the Fig. 3.
This protocol allowed us to observe the activity of internalized
BoNT/A over time. For inhibitor studies (Fig. 4), Triticium
vulgaris Lectin was used at 1 μM, and bafilomycin A1 was used
at titrated concentrations. Both reagents were obtained from
Sigma-Aldrich. BoNT/A neutralizing antibody (4A2–4) (pro-
duced at the US Army Medical Research Institute of Infectious
Diseases) and the control antibody (anti-staphylococcal
enterotoxin B) (Toxin Technology, Sarasota, FL) were simul-
taneously added with BoNT/A at the time of intoxication. The
indicated neutralizing antibody to BoNT/A ratio was based on
approximate molar concentrations.Measuring BoNT/A activity in cell-based assays using
BoNT/A cleavage-sensitive antibodies
For high content imaging, automated image acquisition and
analysis were performed as described previously (Panchal
et al., 2010). Briefly, ES-derived motoneurons were cultured
on Matrigel-coated 96-well plates (BD Falcon Imaging Micro-
plates) and intoxicated with various concentrations of BoNT/A
(0–1000 pM) for 3 h. SNAP-25 protein cleavage was detected
using standard immunofluorescence procedures employing
total SNAP-25 antibody (N-terminal-specific antibody, SMI-81;
Abcam, Cambridge, MA) and full-length SNAP-25 antibodies
(BoNT/A cleavage sensitive (BACS) F2070 antibodies) (Nuss
et al., 2010). The images were acquired using an Opera
confocal high content imager (Opera Model 3842-Quadruple
ExcitationHigh Sensitivity (QEHS), PerkinElmer,Waltham,MA)
through 2 exposures with 20x water objectives. In the first
exposure, the excitations of GFP and fluorophores binding to
total SNAP-25 were directed to sample using 488 and 640 nm
lasers. In the second exposure, 568 nm and UV 350 nm were
used to excite fluorophores binding to full-length SNAP-25 and
nuclei. Images were analyzed within the Opera environment
using Acapella scripts. The algorithm was used to identify
objects such as nuclei based on Hoechst dye and cytoplasm
based on expression of GFP inside the ES-derived motoneur-
ons. The intensity and cellular localization of total SNAP-25
and full-length SNAP-25 were determined by Alexa 568 or
Alexa 633 fluorescence. For each condition, images from 6
fields/well were acquired with the script calculating the
integrated fluorescence intensities in whole cell regions. The
Li-Cor imaging assay was performed using a Li-Cor odyssey
infrared imaging system (Li-Cor, Lincoln, NE), as described
previously (Nuss et al., 2010).
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.scr.2011.01.002.Acknowledgments
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